Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide for Hypothalamic Obesity in Children
NCT01061775Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2010
- Primary completion
- Jul 2013
- Countries
- 1
- Sponsor
- Children's Minnesota
- Modality
- Peptides
- Drugs
- exenatide
- Conditions
- hypothalamic obesity (HO)
01
Overview
Phase 2, open-label trial of exenatide in hypothalamic obesity (HO), sponsored by Children's Minnesota. Primary endpoints: Body Mass Index Change at 24 weeks and Waist to Height Ratio at 24 weeks. Started Jan 2010; status: completed.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Children and young adults (10-21 years) with hypothalamic obesity (BMI >= 95th percentile) at least 6 months post-treatment for craniopharyngioma or suprasellar tumors.
04
Endpoints
Primary
Body Mass Index Change
Waist to Height Ratio
Beyond the preview
Go deeper on NCT01061775.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01061775.